FDA Watch
Similar topics: fda and drug
Health & Fitness
FDA Drug Safety Podcasts
by U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Today: #112 in Health & Fitness, India on our combined chart.
Share this ranking
Claiming needs an RSS feed. Contact us.
Chart positions today · United States
Not on the United States charts we track today.
Not on the United Kingdom charts we track today.
Not on the Canada charts we track today.
Not on the Australia charts we track today.
Not on the Germany charts we track today.
Not on the Brazil charts we track today.
Not on the Mexico charts we track today.
Not on the New Zealand charts we track today.
Not on the Ireland charts we track today.
Not on the Japan charts we track today.
Not on the Philippines charts we track today.
Not on the South Africa charts we track today.
If you like FDA Drug Safety Podcasts, try…
Drug Safety Matters
Also in Health & Fitness
DC EKG
Similar topics: fda and drug
BioCentury This Week
Similar topics: fda and safety
JAMA Medical News
Also in Health & Fitness
Psychopharmacology and Psychiatry Updates
Also in Health & Fitness
Ranking history · United States
No ranking history for this show in United States over the last 7 days.
Latest episodes
-
Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
January 2, 2025 · 5 minSerious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
-
FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause
September 20, 2024 · 4 minListen to an audio podcast of the September 12th, 2024 FDA Drug Safety Communication on rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause.
-
FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)
February 6, 2024 · 4 minListen to FDA Drug Safety Podcast titled, FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab).
-
Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
January 26, 2024 · 4 minListen to FDA Drug Safety Podcast, FDA's preliminary evaluation has not found evidence that use of GLP-1 RAs causes suicidal thoughts/actions.
-
FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi, Sympazan)
December 8, 2023 · 5 minListen to an audio podcast of the November 28, 2023, FDA Drug Safety Communication, FDA warns of rare but serious drug reaction to the antiseizure medicines levetiracetam (Keppra, Keppra XR, Elepsia XR, Spritam) and clobazam (Onfi…
Show 7 more episodesShow fewer episodes
-
FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
May 31, 2023 · 6 minListen to an audio podcast of the May 11, 2023, FDA Drug Safety Communication on warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions
-
FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use
May 10, 2023 · 8 minListen to an audio podcast of the April 13, 2023, FDA Drug Safety Communication, FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use.
-
FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
December 16, 2022 · 4 minFDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
-
FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
July 27, 2022 · 4 minListen to an audio podcast of the June 30, 2022, FDA Drug Safety Communication. Results from a clinical trial show a possible increased risk of death with Copiktra (active ingredient duvelisib) compared to another medicine to treat…
-
FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns
July 7, 2022 · 2 minListen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal…
-
FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging
April 13, 2022 · 5 minListen to an audio podcast of the March 30, 2022 FDA Drug Safety Communication Iodinated Contrast Media
-
FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib)
February 9, 2022 · 4 minListen to an audio podcast of the February 3, 2022, FDA Drug Safety Communication, FDA is investigating a possible increased risk of death with the cancer medicine Ukoniq (umbralisib). We are re-evaluating this risk against the benefits of…
About the show
FDA Drug Safety Podcasts, produced by FDA's Center for Drug Evaluation and Research, provide emerging safety information about drugs in conjunction with the release of Drug Safety Communications. For more information, please visit: www.fda.gov/drugsafetypodcasts